Page last updated: 2024-12-10

alatriopril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alatriopril: shows promise for the treatment of various cardiovascular & salt-retention disorders [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311337
CHEMBL ID325695
SCHEMBL ID49006
MeSH IDM0188191

Synonyms (26)

Synonym
alatriopril
bp-1137
fasidotril
CHEMBL325695
benzyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate
bp1.137
135038-57-2
fasidotril [inn]
n-(3-(3,4-methylenedioxyphenyl)-2-(acetylthio)methyl-1-oxopropyl)-(s)-alanine benzyl ester
bib7hg2v9e ,
n-((s)-alpha-(mercaptomethyl)-3,4-(methylenedioxy)hydrocinnamoyl)-l-alanine, benzyl ester acetate (ester)
unii-bib7hg2v9e
l-alanine, n-(3-(acetylthio)-2-(1,3-benzodioxol-5-ylmethyl)-1-oxopropyl)-, phenylmethyl ester, (s)-
phenylmethyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate
gtpl6501
fasidotril [mi]
l-alanine, n-((2s)-3-(acetylthio)-2-(1,3-benzodioxol-5-ylmethyl)-1-oxopropyl)-, phenylmethyl ester
fasidotril [who-dd]
n-((s)-.alpha.-(mercaptomethyl)-3,4-(methylenedioxy)hydrocinnamoyl)-l-alanine, benzyl ester acetate (ester)
SCHEMBL49006
Q27077285
benzyl ((s)-3-(acetylthio)-2-(benzo[d][1,3]dioxol-5-ylmethyl)propanoyl)-l-alaninate
bp1137
CS-0007264
HY-18207
AKOS040748344

Research Excerpts

Overview

Alatriopril is a dual inhibitor of two cell surface metallopeptidases. These enzymes play important roles in the regulation of arterial blood pressure and renal function.

ExcerptReferenceRelevance
"Alatriopril is a dual inhibitor of two cell surface metallopeptidases which play important roles in the regulation of arterial blood pressure and renal function: the angiotensin I converting enzyme (ACE) which catalyses transformation of angiotensin I to angiotensin II, and the neutral endopeptidase (NEP; EC 3.4.24.11; atriopeptidase), responsible for the degradation of the atrial natriuretic factor (ANF). "( [Systemic and regional hemodynamic effects of a new angiotensin converting enzyme and neutral endopeptidase mixed inhibitor, alatriopril, in the dog].
Lecomte, JM; Richard, V; Thuillez, C, 1993
)
1.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID9850oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]